keyword
https://read.qxmd.com/read/38096740/role-of-ddx1-in-the-oxidative-response-of-ataxia-telangiectasia-patient-derived-fibroblasts
#21
JOURNAL ARTICLE
Mansi Garg, Lei Li, Roseline Godbout
Ataxia Telangiectasia (A-T) is an inherited autosomal recessive disorder characterized by cerebellar neurodegeneration, radiosensitivity, immunodeficiency and a high incidence of lymphomas. A-T is caused by mutations in the ATM gene. While loss of ATM function in DNA repair explains some aspects of A-T pathophysiology such as radiosensitivity and cancer predisposition, other A-T features such as neurodegeneration imply additional roles for ATM outside the nucleus. Emerging evidence suggests that ATM participates in cellular response to oxidative stress, failure of which contributes to the neurodegeneration associated with A-T...
December 9, 2023: Redox Biology
https://read.qxmd.com/read/38071047/-18-f-fdg-pet-ct-metabolic-parameters-and-circulating-tumour-dna-mutation-abundance-in-diffuse-large-b-cell-lymphoma-correlation-and-survival-analysis
#22
JOURNAL ARTICLE
Hai-Qing Xu, Lie-Jing Song, Chong-Yang Ding
OBJECTIVE: To investigate the correlation between 18 Fluoro-deoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) metabolic parameters and peripheral blood circulating tumour DNA (ctDNA) in patients with diffuse large B-cell lymphoma (DLBCL), and the prognostic value of these two types of parameters in predicting progression-free survival (PFS). METHODS: Clinical, PET/CT and ctDNA data of DLBCL patients who underwent peripheral blood ctDNA testing and corresponding PET/CT scans during the same period were retrospectively analyzed...
December 2023: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38049331/-analysis-of-the-feasibility-and-prognostic-value-of-circulating-tumor-dna-monitoring-in-detecting-gene-mutations-in-patients-with-diffuse-large-b-cell-lymphoma-receiving-chimeric-antigen-receptor-t-cell-therapy
#23
JOURNAL ARTICLE
L H Zhou, Y Q Feng, Y X Hu, H Huang
Objective: To explore the prognostic value of circulating tumor DNA (ctDNA) testing in patients with refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy, and to guide the prevention and subsequent treatment of CAR-T-cell therapy failure. Methods: In this study, 48 patients with R/R DLBCL who received CAR-T-cell therapy at the First Affiliated Hospital of Zhejiang University School of Medicine between December 2017 and March 2022 were included...
October 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38039010/circulating-micrornas-as-novel-biomarkers-for-measuring-the-potency-of-ginger-extract-against-cyclophosphamide-toxicity-in-rat-renal-tissues-molecular-and-histopathological-study
#24
JOURNAL ARTICLE
S A Gabr, W M Elsaed, M A Eladl, G A Ghoniem, M El-Sherbiny, K S El-Bayoumi, H Abouhish, A M Desouky, M M Abdel-Aziz, M Eldesoqui, M Elshafey, H A Ebrahim, N S Nosseir, A M R El-Sayed
OBJECTIVE: This study aims to explore underlying molecular variations in the expression of miRNAs in kidney tissues of ginger-treated and non-treated cyclophosphamide (CP)-intoxicated rats. MATERIALS AND METHODS:   A total of 40 adult male Wistar rats were randomly divided into four groups of 10 each: Group I (control: received normal food and water), Group II (received ginger at a dose of 300 mg/kg), Group III (received CP 75 mg/kg, i.p.), and Group IV (received the same dose of CP and ginger extract)...
November 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/37973458/soho-state-of-the-art-updates-and-next-questions-treatment-for-newly-diagnosed-peripheral-t-cell-lymphomas
#25
REVIEW
Jackson S Burton, Nicole C Foley, Neha Mehta-Shah
Although a rare subset of non-Hodgkin lymphomas, peripheral T-cell lymphomas (PTCL) account for a disproportionate proportion of patient mortality. Conventional therapies are derived from experience treating aggressive B-cell lymphomas and center around CHOP-based chemotherapy. However, due to the unique biology and diverse subtypes of PTCL, most patients fail to durably respond to this approach and 5-year survival is only 20% to 30%. There have been multiple attempts to improve outcomes for patients with PTCL...
February 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/37947807/-molecular-diagnostics-for-vitreoretinal-lymphoma
#26
REVIEW
Irina Bonzheim, Julia Salmerón-Villalobos, Daniela Süsskind, Peter Szurman, Florian Gekeler, Martin S Spitzer, Itziar Salaverria, Elias Campo, Sarah E Coupland, Leticia Quintanilla-Martinez, Falko Fend
Primary vitreoretinal lymphoma (PVRL) represents a subtype of intraocular lymphomas, which are a subgroup of malignant lymphomas of the eye. PVRL is considered a special form of primary diffuse large cell lymphoma (DLBCL) of the CNS (central nervous system) (PCNSL) and arises primary or secondary to PCNSL. According to the cell of origin (COO) classification of DLBCL, PVRL largely belongs to the activated B‑cell (ABC) type of DLBCL. Based on a recently established genetic-biological classification of DLBCL, PCNSL and thus also PVRL belong to a group of DLBCL of the MYD88/CD79B-mutated (MCD) or cluster 5 subtype, which often shows extranodal manifestations and MYD88 and CD79A mutations as well as CDKN2A deletions...
November 10, 2023: Pathologie (Heidelb)
https://read.qxmd.com/read/37930608/measurable-residual-disease-monitoring-in-lymphoma
#27
REVIEW
Brian Cuzzo, Andrew Lipsky, Hua-Jay J Cherng
PURPOSE OF REVIEW: The utility of analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and disease in the bone marrow as an adjunctive tool in caring for hematologic cancer patients is expanding. This holds true for lymphoma where these biomarkers are being explored as a means of genotyping and quantifying disease. Regarding the latter, they can be used to monitor measurable residual disease (MRD) during and after treatment. This holds potential for aiding clinical decisions amidst treatment, detecting earlier relapse, and improving prognostication...
November 6, 2023: Current Hematologic Malignancy Reports
https://read.qxmd.com/read/37919456/torque-teno-virus-plasma-dna-load-a-novel-prognostic-biomarker-in-car-t-therapy
#28
JOURNAL ARTICLE
Ana Benzaquén, Estela Giménez, Gloria Iacoboni, Manuel Guerreiro, Rafael Hernani, Eliseo Albert, Cecilia Carpio, Aitana Balaguer, Ariadna Pérez, Carlos S de la Asunción, Mario Andrés Sánchez-Salinas, Pedro Chorão, José Luis Piñana, Francisco Beas, Juan Montoro, Juan Carlos Hernández-Boluda, Ana Facal, Blanca Ferrer, Marta Villalba, Paula Amat, María Dolores Goméz, Diana Campos, María José Terol, Jaime Sanz, Pere Barba, David Navarro, Carlos Solano
Torque Teno Virus (TTV) is a single-stranded circular DNA virus which has been identified as a surrogate marker of immune competence in transplantation. In this study we investigated the dynamics of plasma TTV DNAemia in 79 adult patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory large B-cell lymphoma, also evaluating the impact of TTV on immunotoxicities, response and survival outcomes. After lymphodepleting therapy, TTV DNA load was found to decrease slightly until reaching nadir around day 10, after which it increased steadily until reaching maximum load around day 90...
January 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/37913572/berberine-derivative-dcz0358-induce-oxidative-damage-by-ros-mediated-jnk-signaling-in-dlbcl-cells
#29
JOURNAL ARTICLE
Qilin Feng, Ke Hu, Huifang Hu, Yumeng Lu, Hui Zhang, Guanli Wang, Qikai Zhang, Zhijian Xu, Xuejie Gao, Xinyan Jia, Huabin Zhu, Dongliang Song, Hongfei Yi, Yu Peng, Xiaosong Wu, Bo Li, Weiliang Zhu, Jumei Shi
The most common neoplasm among adult lymphomas is diffuse large B-cell lymphoma (DLBCL), typically characterized by pain-free and progressive lymph node enlargement. Due to high heterogeneity of DLBCL, 30-40 % of patients are resistant to R-CHOP standard chemoimmunotherapy. DCZ0358 is a new compound designed and synthesized from berberine by our group and the molecular mechanism by which it inhibited DLBCL growth has attracted our widespread attention. In this study, we employed the CCK8 assay to reveal that DCZ0358 inhibited proliferation in a dependent manner of time and dosage of DLBCL cells...
October 30, 2023: International Immunopharmacology
https://read.qxmd.com/read/37909016/prognostic-significance-of-the-systemic-immune-inflammation-index-in-patients-with-extranodal-natural-killer-t-cell-lymphoma
#30
JOURNAL ARTICLE
Tao Hai, Wanchun Wu, Kexin Ren, Na Li, Liqun Zou
BACKGROUND: The systemic immune-inflammation index (SII) is based on the neutrophil, platelet, and lymphocyte counts, and has been identified as a prognostic marker in multiple types of cancer. However, the potential value of the SII for predicting survival outcomes in patients with extranodal natural killer/T-cell lymphoma (ENKTCL) has not been investigated thus far. METHOD: This study included 382 patients with ENKTCL treated with asparaginase-base regimens from 2021 to 2017 in West China Hospital (Chengdu, China)...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37908506/the-use-of-cell-free-dna-cfdna-for-mutational-screening-of-multiple-myeloma
#31
JOURNAL ARTICLE
A-M Joëlle Marivel, Yafeng Ma, Therese M Becker, Anvita Verma, Steven Trieu, Tara L Roberts, Silvia C W Ling
Multiple myeloma (MM) is an incurable haematological malignancy which relies heavily on bone marrow biopsies for disease monitoring and prediction of treatment response. In recent years, liquid biopsy derived cell-free DNA (cfDNA) has emerged as alternative for invasive biopsies. This pilot study aimed to evaluate the feasibility of using cfDNA for the detection of oncogenic mutations in the mitogen-activated protein kinase (MAPK) pathway genes NRAS, KRAS, and BRAF in MM patients. Matched peripheral blood and bone marrow aspirates were collected from thirteen MM patients at various disease stages...
2023: Leukemia Research Reports
https://read.qxmd.com/read/37875708/role-of-histone-deacetylase-inhibitor-in-diabetic-painful-neuropathy
#32
JOURNAL ARTICLE
Vikram Thakur, Mayra A Gonzalez, Maria Parada, Robert D Martinez, Munmun Chattopadhyay
Diabetic painful neuropathy (DPN) is one of the most detrimental complications of diabetes. Alterations in neuroinflammatory mediators play significant roles in the development of DPN. Infiltration of the neutrophils and monocyte/macrophages contributes substantial role in the degenerative process of the distal sciatic nerve by forming neutrophil extracellular traps (NETs) under diabetic condition. Citrullination of histones due to increase in protein arginine deiminase (PAD) enzyme activity under hyperglycemia may promote NET formation, which can further increase the cytokine production by activating macrophages and proliferation of neutrophils...
October 24, 2023: Molecular Neurobiology
https://read.qxmd.com/read/37875309/-chidamide-induces-ebv-lytic-infection-and-acts-synergistically-with-tenofovir-eliminate-ebv-positive-burkitt-lymphoma
#33
JOURNAL ARTICLE
Linyan Xu, Meng Zhang, Dongyun Tu, Ziyi Lu, Tianyi Lu, Dongshen Ma, Yi Zhou, Shuo Zhang, Yuhan Ma, Dongmei Yan, Xiangmin Wang, Wei Sang
Epstein-Barr virus (EBV) is a type of human gamma-herpesvirus, and its reactivation plays an important role in the development of EBV-driven Burkitt lymphoma (BL). Despite intensive chemotherapy, the prognosis for patients with refractory or relapsed BL remains unfavorable, and a definitive method to completely eliminate latent EBV infection is lacking. Previous studies have demonstrated that histone deacetylase (HDAC) inhibitors can induce the transition of EBV from latency to the lytic phase. The lytic activation of EBV can be inhibited by tenofovir, a potent inhibitor of DNA replication...
October 24, 2023: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/37867373/prognostic-value-of-differential-expression-of-polymerase-eta-gene-in-nonresponding-patients-with-diffuse-large-b-cell-lymphoma
#34
JOURNAL ARTICLE
Aditi Sharma, Ashim Das, Amanjit Bal, Radhika Srinivasan, Pankaj Malhotra, Gaurav Prakash, Rajendar Kumar
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkins lymphoma. After the introduction of rituximab therapy like rituximab, cyclophosphamide, doxorubicin vincristine, prednisolone, there has been considerable improvement in the 5-year overall survival in this group of patients, but the nonresponding patients are a challenge to the clinician. The translesion polymerases are unique polymerases that make cells tolerant to DNA damage. Many point mutations are introduced owing to their inherent property of bypassing the points of lesions, preventing the cell from stalling replication...
October 23, 2023: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://read.qxmd.com/read/37854161/superior-clinical-outcomes-in-patients-with-non-small-cell-lung-cancer-harboring-multiple-alk-fusions-treated-with-tyrosine-kinase-inhibitors
#35
JOURNAL ARTICLE
Qi Wei, Yuanyuan Zhang, Yongsheng Wang, Aakash Desai, Sihan Tan, Qin Huang, Xin Pu, Panwen Tian, Yalun Li
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase ( ALK ) fusions may benefit from ALK-tyrosine kinase inhibitors (ALK-TKIs). However, few studies have analyzed the clinical outcome in patients harboring multiple ALK fusions, including double or triple ALK fusions. Here, our study aimed to analyze the impact of harboring multiple ALK fusions on the efficacy of receiving ALK-TKIs in NSCLC patients. METHODS: A total of 125 patients with ALK -rearranged NSCLC detected by targeted capture DNA-based next-generation sequencing (NGS) at West China Hospital were enrolled...
September 28, 2023: Translational Lung Cancer Research
https://read.qxmd.com/read/37838941/obinutuzumab-based-drug-free-macromolecular-therapeutics-synergizes-with-topoisomerase-inhibitors
#36
JOURNAL ARTICLE
M Tommy Gambles, Douglas Sborov, Paul Shami, Jiyuan Yang, Jindřich Kopeček
Drug-Free Macromolecular Therapeutics (DFMT) utilizes modified monoclonal antibodies (or antibody fragments) to generate antigen-crosslinking induced apoptosis in target cells. DFMT is a two-component system containing a morpholino oligonucleotide (MORF1) modified antibody (Ab-MORF1) and human serum albumin conjugated with multiple copies of complementary morpholino oligonucleotide (MORF2), (HSA-(MORF2)x ). The two components recognize each other via Watson-Crick base pairing complementation of their respective MORFs...
October 15, 2023: Macromolecular Bioscience
https://read.qxmd.com/read/37806433/recommendations-for-cell-free-dna-assay-validations-a-joint-consensus-recommendation-of-the-association-for-molecular-pathology-and-college-of-american-pathologists
#37
REVIEW
Christina M Lockwood, Laetitia Borsu, Milena Cankovic, Jonathan S L Earle, Christopher D Gocke, Meera Hameed, Danielle Jordan, Jean R Lopategui, Mrudula Pullambhatla, Jacquelyn Reuther, Kandelaria M Rumilla, Laura J Tafe, Robyn L Temple-Smolkin, Panieh Terraf, Apostolia M Tsimberidou
Diagnosing, selecting therapy for, and monitoring cancer in patients using a minimally invasive blood test represents a significant advance in precision medicine. Wide variability exists in how circulating tumor DNA (ctDNA) assays are developed, validated, and reported in the literature, which hinders clinical adoption and may negatively impact patient care. Standardization is needed for factors affecting ctDNA assay performance and reporting, including pre-analytical variables, analytical considerations, and elements of laboratory assay reporting...
October 6, 2023: Journal of Molecular Diagnostics: JMD
https://read.qxmd.com/read/37736096/case-report-unedited-allogeneic-chimeric-antigen-receptor-t-cell-bridging-to-conditioning-free-hematopoietic-stem-cell-transplantation-for-a-child-with-refractory-burkitt-lymphoma
#38
Xiaomin Yang, Chengjuan Luo, Juan Qian, Xiaohang Huang, Jian Zhang, Jianmin Wang, Changying Luo, Xia Qin, Benshang Li, Jing Chen
PURPOSE: Burkitt lymphoma (BL) is the most common tumor of non-Hodgkin's lymphoma (NHL) in children, accounting for about 40% of cases. Although different combined short-course chemotherapies have achieved a good effect, refractory/relapsed BL has a poor prognosis with cure rates less than 30%. Chimeric antigen receptor T cell (CAR-T) therapy has developed rapidly in recent years and achieved excellent results in acute lymphoblastic leukemia (ALL). However, in some cases, there is a failure to produce autologous CAR-T cells because of T-cell dysfunction...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37716070/aflatoxin-b1-triggers-apoptosis-in-rabbit-hepatocytes-via-mediating-oxidative-stress-and-switching-on-the-mitochondrial-apoptosis-pathway
#39
JOURNAL ARTICLE
Lu Zhang, Shaowen Shi, Ying Liu, Yuqing Cui, Yixuan Zhu, Yongzhan Bao, Baojiang Chen, Wanyu Shi
Aflatoxin B1 (AFB1) is considered the most toxic carcinogenic compound, and exposure to AFB1 is highly associated with hepatocellular carcinoma. The aim of this study was to investigate the effects of different doses of AFB1 on growth performance and the liver of rabbits, as well as explore its underlying mechanisms. A total of eighty 30-day-old meat rabbits were randomly divided into four treatments. The control group was fed a pollution-free diet, while the AFL, AFM, and AFH groups were fed contaminated diets containing 13 μg/kg, 19 μg/kg, and 25 μg/kg of AFB1, respectively...
September 14, 2023: Ecotoxicology and Environmental Safety
https://read.qxmd.com/read/37706178/novel-ppfia1-alk-alk-c2orf91-intergenic-double-fusion-responded-well-to-alectinib-in-an-advanced-lung-adenocarcinoma-patient-a-case-report
#40
Lingxin Yan, Jiayu Zheng, Qingyun Pan, Yuxian Liang, Pengli Yu, Quanfang Chen
Non-small cell lung cancers (NSCLCs) with anaplastic lymphoma kinase (ALK)-rearrangement have favorable responses to ALK inhibitors. However, ALK fusion mutations harbored approximately 90 distinct fusion partners. Patients with different ALK fusions might respond distinctly to different-generation ALK inhibitors. In this case report, we identified a novel non-reciprocal ALK fusion, ALK-C2orf91 (intergenic) (A19: intergenic) and PPFIA1 - ALK (P2:A20), by next-generation DNA sequencing in an advanced lung adenocarcinoma patient...
2023: Frontiers in Oncology
keyword
keyword
97504
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.